Published in Blood on July 15, 2006
Estimating tissue iron burden: current status and future prospects. Br J Haematol (2015) 0.81
Brown adipose tissue activity controls triglyceride clearance. Nat Med (2011) 6.76
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med (2006) 4.04
Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics (2008) 2.61
Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev (2015) 2.11
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med (2011) 1.89
Mucopolysaccharidosis VI. Orphanet J Rare Dis (2010) 1.87
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Management guidelines for mucopolysaccharidosis VI. Pediatrics (2007) 1.61
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A (2005) 1.58
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol (2006) 1.44
Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol (2005) 1.41
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood (2010) 1.41
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat (2007) 1.30
The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr (2011) 1.27
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr (2009) 1.27
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 1.26
Assessment of resident surgical skills: is testing feasible? Am J Obstet Gynecol (2005) 1.25
International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A (2014) 1.19
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer (2007) 1.17
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci (2009) 1.17
The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med (2008) 1.15
Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis (2013) 1.14
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica (2006) 1.13
The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab (2013) 1.12
Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals (2007) 1.12
Assessing quality obstetrical care: development of standardized measures. Jt Comm J Qual Patient Saf (2006) 1.12
Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med (2010) 1.11
Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI. J Pediatr Rehabil Med (2010) 1.09
Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med (2005) 1.05
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis (2011) 1.04
Initial outcomes from a 4-week follow-up study of the Text4baby program in the military women's population: randomized controlled trial. J Med Internet Res (2014) 1.03
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica (2010) 1.01
Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med (2009) 1.01
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol (2005) 1.00
Iron metabolism and iron chelation in sickle cell disease. Acta Haematol (2009) 1.00
Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med (2010) 0.99
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A (2014) 0.98
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol (2013) 0.97
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin Pharmacokinet (2008) 0.96
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis (2011) 0.95
Does liver biopsy overestimate liver iron concentration? Blood (2006) 0.95
Orthopedic management of mucopolysaccharide disease. J Pediatr Rehabil Med (2010) 0.94
A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies. ACS Nano (2012) 0.93
John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudes. Jt Comm J Qual Patient Saf (2007) 0.92
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet (2003) 0.92
Erythrocytapheresis: Do Not Forget a Useful Therapy! Transfus Med Hemother (2008) 0.92
Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol (2011) 0.91
Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol Dis (2003) 0.91
Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis (2012) 0.90
The economic burden of home care for children with HIV and other chronic illnesses. Am J Public Health (2005) 0.90
Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol (2007) 0.90
Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry (2010) 0.90
High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One (2012) 0.88
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol (2008) 0.88
Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry (2010) 0.88
A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood (2011) 0.87
Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. Magn Reson Imaging (2010) 0.87
Economic and psychologic costs for maternal caregivers of gastrostomy-dependent children. J Pediatr (2004) 0.87
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica (2011) 0.86
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements. Haematologica (2008) 0.86
Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer (2007) 0.86
Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients. Ann Hematol (2012) 0.85
Comparison of objective, structured assessment of technical skills with a virtual reality hysteroscopy trainer and standard latex hysteroscopy model. J Reprod Med (2007) 0.85
Treatment of hepatitis C virus infection in thalassemia. Ann N Y Acad Sci (2005) 0.85
Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer (2008) 0.85
Open, cyclic, and bicyclic compounds of double silylated phosphorus and boron. Dalton Trans (2004) 0.85
Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major. Ann N Y Acad Sci (2005) 0.85
Intraperitoneal injection improves the uptake of nanoparticle-labeled high-density lipoprotein to atherosclerotic plaques compared with intravenous injection: a multimodal imaging study in ApoE knockout mice. Circ Cardiovasc Imaging (2013) 0.84
Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol (2011) 0.84
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol (2010) 0.84
Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. PLoS One (2011) 0.84
DWI of the brain: postmortal DWI of the brain in comparison with in vivo data. Forensic Sci Int (2012) 0.84
Clinical guidelines for occupational lifting in pregnancy: evidence summary and provisional recommendations. Am J Obstet Gynecol (2013) 0.84
Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome). JIMD Rep (2013) 0.83